Evidence map›Paper›PMID 42054252›Full record

ArticleDigestive diseases (Basel, Switzerland)2026

Bone Mineral Density Does Not Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial.

Maximilian Thormann, Andreas Wienke, Ricarda Seidensticker, Kerstin Schütte, Christoph J Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Maximilian ThormannDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany, maximilian.thormann@charite.de.
Andreas WienkeInstitute of Medical Epidemiology, Biometry and Informatics, University of Halle, Halle, Germany.
Ricarda SeidenstickerDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Kerstin SchütteDepartment of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken Marienhospital, Osnabrück, Germany.
Christoph J ZechRadiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Christian LoeweSection of Cardiovascular and Interventional Radiology, Department of Bioimaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Otto van DeldenDepartment of Radiology and Nuclear Medicine, Amsterdam Academic University Medical Centers, Amsterdam, The Netherlands.
Vincent VandecaveyeDepartment of Radiology, University Hospitals Leuven, Leuven, Belgium.
Chris VerslypeDepartment of Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Bernhard GebauerDepartment of Radiology, Charité - University Medicine Berlin, Berlin, Germany.
Christian SengelRadiology Department, Grenoble University Hospital, La Tronche, France.
Irene BargelliniDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Roberto IezziFondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radiologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy.
Thomas BergDivision of Hepatology, Department of Medicine II, University of Leipzig Medical Center, Leipzig, Germany.
Heinz KlümpenDepartment of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Julia BenckertCharité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Berlin, Germany.
Antonio GasbarriniFondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Holger AmthauerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Bruno SangroLiver Unit, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
Peter MalfertheinerDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
Maciej PechUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Jan BorggrefeDepartment of Radiology, Johannes Wessling Krankenhaus Minden, Ruhr University Bochum, Minden, Germany.
Jens RickeDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Max SeidenstickerDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Alexey SurovDepartment of Radiology, Johannes Wessling Krankenhaus Minden, Ruhr University Bochum, Minden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLow bone mineral density (BMD) is an increasingly recognized marker of skeletal frailty, associated with higher fracture risk and mortality in cancer patients. In advanced hepatocellular carcinoma (HCC), however, the prognostic significance of baseline BMD remains unclear. This exploratory subanalysis of the SORAMIC trial evaluated whether CT-derived BMD predicts overall survival (OS) in patients with unresectable HCC.

methodsIn this exploratory post hoc study, 342 patients with unresectable HCC and preserved liver function (Child-Pugh ≤B7) were enrolled in the palliative arm of the SORAMIC trial and randomized to receive either sorafenib monotherapy (n = 170) or selective internal radiation therapy (SIRT) plus sorafenib (n = 172). BMD (in Hounsfield units [HU]) was measured at the third lumbar vertebra on pre-treatment contrast-enhanced CT scans. Patients were stratified into low and high BMD groups using three definitions: the cohort median (139.5 HU for men, 130.0 HU for women), <160 HU for men and <175 HU for women (Meister criteria), and <160 HU (Jang criteria). Cox regression analyses assessed the impact of BMD on OS.

resultsMedian OS in the overall cohort was 11.1 months. No significant association between BMD and OS was observed in the entire cohort or within the sorafenib and SIRT/sorafenib subgroups. Similar nonsignificant results occurred in alcohol-, viral-, and metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease-induced HCC subgroups.

conclusionBaseline CT-derived BMD does not predict OS in advanced HCC patients, indicating it is not a robust prognostic biomarker in this setting. Low BMD does not affect a patient's resilience to SIRT.

Indexed as

Bone mineral densityHepatocellular carcinomaPrognosisSelective internal radiation therapySorafenib

Identifiers

PMID42054252
PMCPMC13363108

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.